Previous 10 | Next 10 |
2023-11-13 06:58:59 ET More on Milestone Pharmaceuticals Seeking Alpha’s Quant Rating on Milestone Pharmaceuticals Historical earnings data for Milestone Pharmaceuticals Financial information for Milestone Pharmaceuticals For further details see: M...
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates Canada NewsWire New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYST ™ , the conditionally approved brand name f...
Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023 Canada NewsWire E tripamil, an investigational drug, showed statistically significant reduction in ventricula...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Milestone Pharmaceuticals Inc. (MIST) is expected to report $-0.38 for Q3 2023
Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR Canada NewsWire Cardiac Electrophysiology Key Opinion Leaders joining the webcast include A. John Camm , MD, and Sean Pokorney , MD ...
Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil Canada NewsWire Submission seeks approval for treatment of an abnormal heart rhythm, Paroxysmal Supraventricular Tachycardia or PSVT Comprehensive data packa...
Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023 Canada NewsWire MONTREAL and CHARLOTTE, N.C. , Sept. 27, 2023 /CNW/ -- Milestone Pharmaceut...
Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference Canada NewsWire MONTREAL and CHARLOTTE, N.C. , Sept. 5, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on ...
2023-08-10 12:24:31 ET Milestone Pharmaceuticals press release ( NASDAQ: MIST ): Q2 GAAP EPS of -$0.37 beats by $0.02 . As of June 30, 2023, Milestone had cash, cash equivalents, and short-term investments of $87.6 million and 33.4 million common shares issued and outs...
News, Short Squeeze, Breakout and More Instantly...
Milestone Pharmaceuticals Inc. Company Name:
MIST Stock Symbol:
NYSE Market:
Milestone Pharmaceuticals Inc. Website:
MONTREAL and CHARLOTTE, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will host Part I of its virtual investor educ...
MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies Global Healthcare Conference being held in New York City, NY from June 4-6, 2024. ...
MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the United States Food and Drug A...